Cargando…

Tyrosine kinase inhibitors in HER2‐positive breast cancer brain metastases: A systematic review and meta‐analysis

BACKGROUND: Small tyrosine kinase inhibitors (TKIs) show activity against breast cancer brain metastases (BCBM) of the human epidermal growth factor receptor 2 (HER2)‐positive subtype. This meta‐analysis aimed to objectively explore the efficacy and safety of TKIs. METHODS: Electronic databases were...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yu, Yushuai, Huang, Kaiyan, Lin, Yuxiang, Zhang, Jie, Song, Chuangui
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2023
Materias:	RESEARCH ARTICLES
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10417165/ https://www.ncbi.nlm.nih.gov/pubmed/37255389 http://dx.doi.org/10.1002/cam4.6180

Ejemplares similares

Efficacy and safety of neoadjuvant therapy for HER2-positive early breast cancer: a network meta-analysis
por: Zhang, Jie, et al.
Publicado: (2021)

The impact of chemotherapy and survival prediction by machine learning in early Elderly Triple Negative Breast Cancer (eTNBC): a population based study from the SEER database
por: Huang, Kaiyan, et al.
Publicado: (2022)

Efficacy of tyrosine kinase inhibitors for the treatment of patients with HER2-positive breast cancer with brain metastases: a systematic review and meta-analysis
por: Nader-Marta, G., et al.
Publicado: (2022)

Tyrosine Kinase Inhibitors in the Combination Therapy of HER2 Positive Breast Cancer
por: Yang, Xue, et al.
Publicado: (2020)

HER2-positive breast cancer and tyrosine kinase inhibitors: the time is now
por: Schlam, Ilana, et al.
Publicado: (2021)

Clinical updates on tyrosine kinase inhibitors in HER2-positive breast cancer
por: Singh, Desh Deepak, et al.
Publicado: (2022)

Comparative Efficacy of Tyrosine Kinase Inhibitors and Antibody–Drug Conjugates in HER2-Positive Metastatic Breast Cancer Patients with Brain Metastases: A Systematic Review and Network Meta-Analysis
por: Wang, Yan, et al.
Publicado: (2022)

The role of irreversible pan-HER tyrosine kinase inhibitors in the treatment of HER2-Positive metastatic breast cancer
por: Wu, Zihong, et al.
Publicado: (2023)

Impact of breast surgery on survival of patients with stage IV breast cancer: a SEER population-based propensity score matching analysis
por: Lin, Yuxiang, et al.
Publicado: (2020)

Mechanistic Modeling of Central Nervous System Pharmacokinetics and Target Engagement of HER2 Tyrosine Kinase Inhibitors to Inform Treatment of Breast Cancer Brain Metastases
por: Li, Jing, et al.
Publicado: (2022)

Epidemiology and a Predictive Model of Prognosis Index Based on Machine Learning in Primary Breast Lymphoma: Population-Based Study
por: Yu, Yushuai, et al.
Publicado: (2023)

Escape from HER family tyrosine kinase inhibitor therapy by the kinase inactive HER3
por: Sergina, Natalia V., et al.
Publicado: (2007)

HER2 therapy. Small molecule HER-2 tyrosine kinase inhibitors
por: Spector, Neil, et al.
Publicado: (2007)

Tyrosine Kinase Inhibitors Are Promising Therapeutic Tools for Cats with HER2-Positive Mammary Carcinoma
por: Gameiro, Andreia, et al.
Publicado: (2021)

HER2-Selective and Reversible Tyrosine Kinase Inhibitor Tucatinib Potentiates the Activity of T-DM1 in Preclinical Models of HER2-positive Breast Cancer
por: Olson, Devra, et al.
Publicado: (2023)

Comparative docking analysis of tyrosine kinase inhibitors with HER2 and HER4 receptors
por: Sonar, Priyanka, et al.
Publicado: (2022)

The Receptor Tyrosine Kinase TrkA Is Increased and Targetable in HER2-Positive Breast Cancer
por: Griffin, Nathan, et al.
Publicado: (2020)

34. TARGETED THERAPY FOR HER2-POSITIVE BREAST CANCER BRAIN METASTASES: A SYSTEMATIC REVIEW AND META-ANALYSIS
por: Erickson, Anders, et al.
Publicado: (2020)

Systemic Therapy for Patients with HER2-Positive Breast Cancer and Brain Metastases: A Systematic Review and Meta-Analysis
por: Werter, Inge M., et al.
Publicado: (2022)

Real-World Analysis of the Efficacy and Safety of a Novel Irreversible HER2 Tyrosine Kinase Inhibitor Pyrotinib in Patients with HER2-Positive Metastatic Breast Cancer
por: Sun, Ying, et al.
Publicado: (2021)

Novel Anti-HER2 Antibody-Drug Conjugates Versus T-DM1 for HER2-Positive Metastatic Breast Cancer After Tyrosine Kinase Inhibitors Treatment
por: Ji, Chenchen, et al.
Publicado: (2023)

The multitargeted receptor tyrosine kinase inhibitor sunitinib induces resistance of HER2 positive breast cancer cells to trastuzumab-mediated ADCC
por: Guti, Eliza, et al.
Publicado: (2022)

Evaluation on efficacy and safety of tyrosine kinase inhibitors plus radiotherapy in NSCLC patients with brain metastases
por: Luo, Shuimei, et al.
Publicado: (2015)

HER2-Targeted Tyrosine Kinase Inhibitors Cause Therapy-Induced-Senescence in Breast Cancer Cells
por: McDermott, Martina S. J., et al.
Publicado: (2019)

HER2 Oncogenic Function Escapes EGFR Tyrosine Kinase Inhibitors via Activation of Alternative HER Receptors in Breast Cancer Cells
por: Kong, Anthony, et al.
Publicado: (2008)

Risk factors for the development of brain metastases in patients with HER2-positive breast cancer
por: Maurer, Christian, et al.
Publicado: (2018)

Brain Metastases in HER2-Positive Breast Cancer: Current and Novel Treatment Strategies
por: Garcia-Alvarez, Alejandro, et al.
Publicado: (2021)

Combination of radiotherapy and targeted therapy for HER2-positive breast cancer brain metastases
por: Yang, Xiaojing, et al.
Publicado: (2023)

Pyrotinib-based treatments in HER2-positive breast cancer patients with brain metastases
por: Ma, Xiaoping, et al.
Publicado: (2022)

Role of the HGF/c-MET tyrosine kinase inhibitors in metastasic melanoma
por: Demkova, Lucia, et al.
Publicado: (2018)

Efficacy and Safety of Radiotherapy Combined with Pyrotinib in the Treatment of HER2-Positive Breast Cancer with Brain Metastases
por: Huang, Jie, et al.
Publicado: (2023)

Brain metastases in resected non-small cell lung cancer: The impact of different tyrosine kinase inhibitors
por: Yun, Po-Jen, et al.
Publicado: (2019)

Brain metastases in Asian HER2-positive breast cancer patients: anti-HER2 treatments and their impact on survival
por: Yap, Y S, et al.
Publicado: (2012)

RON tyrosine kinase mutations in brain metastases from lung cancer
por: Milan, Melissa, et al.
Publicado: (2018)

How we treat HER2-positive brain metastases
por: Stavrou, E., et al.
Publicado: (2021)

Genetic heterogeneity and actionable mutations in HER2-positive primary breast cancers and their brain metastases
por: De Mattos-Arruda, Leticia, et al.
Publicado: (2018)

Molecular Mechanisms Associated with Brain Metastases in HER2-Positive and Triple Negative Breast Cancers
por: Bryan, Sarah, et al.
Publicado: (2021)

74. EFFICACY OF HER2-TARGETED THERAPY IN HER2-POSITIVE BREAST CANCER BRAIN METASTASES: A NATIONAL ANALYSIS
por: Hulsbergen, Alexander, et al.
Publicado: (2020)

Glycodelin As A Biomarker Of Advanced Lung Adenocarcinoma Brain Metastases In Patients Treated With EGFR Tyrosine Kinase Inhibitors
por: Ni, Zexu, et al.
Publicado: (2019)

Neratinib, an irreversible pan erB receptor tyrosine kinase inhibitor active for advanced HER2(+ )breast cancer
por: Cortés-Funes, H, et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_8r3cdb2evgmnd3526lu50pk5d5